Status:

COMPLETED

A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants

Lead Sponsor:

Eli Lilly and Company

Conditions:

Healthy

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

The purpose of this study is to assess how fast galcanezumab gets into the blood stream and how long it takes the body to remove it. Information about side effects will be collected. The study is open...

Eligibility Criteria

Inclusion

  • Participants who are native Chinese (all 4 biological grandparents and both biological parents to be of Chinese origin)
  • Participants who are overtly healthy males or females, as determined by medical history and physical examination

Exclusion

  • Participants who are currently enrolled in a clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study
  • Participants who have participated, within the last 30 days, in a clinical study involving an investigational product. If the previous investigational product has a long half-life, 5 half-lives or 30 days (whichever is longer) should have passed
  • Participants who have received treatment with any CGRP (calcitonin gene related peptide) antibody (including galcanezumab), or antibody against CGRP receptor (including erenumab), or have received biologic agents (such as monoclonal antibodies) within 4 months or 5 half-lives (whichever is longer) prior to dosing
  • Participants who have a history of multiple or severe allergies or has had an anaphylactic reaction to prescription or non-prescription drugs or food
  • women who are lactating
  • Participants who show evidence of positive human immunodeficiency virus antibodies, or positive hepatitis C antibody, or positive hepatitis B surface antigen, or active tuberculosis

Key Trial Info

Start Date :

November 20 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 21 2020

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT04085289

Start Date

November 20 2019

End Date

May 21 2020

Last Update

June 15 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

HuaShan Hospital Affiliated To Fudan University

Shanghai, Shanghai Municipality, China, 20040